IndraLab

Statements

CALM1 binds NP. 36 / 36
| 36
sparser
"The incidence of treatment-related adverse event (TRAE)-related treatment discontinuation was 13.3% (4/30) in the Cam-NP group and 17.9% (5/28) in the NP group, with no significant difference between the 2 groups ( P  = ."
40554667
sparser
"Discontinuations in the Cam-NP group were primarily due to bradycardia, pneumonitis, reactive cutaneous capillary endothelial proliferation (RCCEP), and meningitis."
40554667
sparser
"The ORR in the Cam-NP group was 33.3%, which was significantly higher than the control group ( P  = ."
40554667
sparser
"Further analysis of patients who underwent at least one computed tomography assessment revealed an ORR of 35.7% in the Cam-NP group, representing a 19.9% improvement over the single-agent cohort, though this did not reach statistical significance ( P  = ."
40554667
sparser
"The median progression-free survival (mPFS) was 5.62 months in the Cam-NP group, extending the mPFS of the single-agent chemotherapy group by 1.41 months with statistical significance (HR 0.33, P  = ."
40554667
sparser
"Lastly, there was a noticeable upward trend in median overall survival (mOS) in the Cam-NP group, which reached 9.8 months, extending the mOS of the single-agent group by 2.63 months (HR 0.62, P  = 0.087)."
40554667
sparser
"Elevated liver aminotransferase levels and skin toxicity were more frequently observed in the Cam-NP group."
40554667
sparser
"As a result, AC and PC bound and internalized anti-ICAM NP mainly by the CAM pathway (not clathrin pits or caveoli), yet, at a lower level than EC: by 1 h, AC and PC bound 79 and 95 NP/cell vs 200 NP/cell for EC, and internalized 42 and 43 NP/cell vs 110 NP/cell for EC."
24573530
sparser
"This multicenter, randomized phase II trial evaluated the efficacy of nab-paclitaxel plus camrelizumab (Cam-NP) versus nab-paclitaxel alone (NP) in patients with advanced gastric adenocarcinoma resistant to prior treatment."
40554667
sparser
"Patients were randomized to receive either Cam-NP or NP until disease progression, intolerable toxicity, or consent withdrawal."
40554667
sparser
"At a median follow-up of 34.5 months, the Cam-NP group achieved a significantly higher ORR (33.3% vs. 10.7%; P  = ."
40554667
sparser
"Median response duration also favored Cam-NP (4.64 vs. 2.96 months; P  = ."
40554667
sparser
"While the Cam-NP group showed a longer OS (9.8 vs. 7.2 months; P  = ."
40554667
sparser
"Cam-NP significantly improved ORR and PFS compared to NP as a second-line treatment for advanced gastric adenocarcinoma."
40554667
sparser
"Of these, 31 were assigned to the Cam-NP arm, and 30 to the NP arm."
40554667
sparser
"Three patients were excluded before treatment initiation due to ascites requiring drainage (Cam-NP arm, n  = 1; NP arm, n  = 1) and withdrawal of consent (NP arm, n  = 1)."
40554667
sparser
"The final analysis included 58 patients, with 30 in the Cam-NP arm and 28 in the NP arm."
40554667
sparser
"The median number of therapy cycles was 5.5 in the Cam-NP arm (range, 1-39) and 2 in the NP arm (range, 1-6) ( P  < ."
40554667
sparser
"Two patients in the Cam-NP arm continued PD-1 inhibitor therapy beyond 18 cycles, based on the treating physician’s recommendation."
40554667
sparser
"The proportion of patients receiving at least 2 cycles of treatment was significantly higher in the Cam-NP arm (96.7%) compared to the NP arm (78.6%) ( P  = ."
40554667
sparser
"Following disease progression, 23.3% of patients in the Cam-NP group received additional immune checkpoint inhibitors, while 25% of patients in the NP group received PD-1 inhibitors."
40554667
sparser
"As the primary endpoint, an objective response was achieved in 10 of 30 patients (ORR: 33.3%, 95% CI, 15.4-51.2%) in the Cam-NP arm and 3 of 28 patients (ORR: 10.7%, 95% CI, 0-22.9%) in the NP arm ( P  = 0.039)."
40554667
sparser
"Two patients in the Cam-NP group were assessed as having a complete response (CR) after 4 and 9 cycles of combination PD-1 inhibitor therapy, respectively."
40554667
sparser
"The disease control rate (DCR) was significantly higher in the Cam-NP arm (DCR = 90%, 95% CI, 78.6-100%) compared to the NP arm (DCR = 50%, 95% CI, 30.3-69.7%) ( P  = 0.001)."
40554667
sparser
"At the time of analysis, 24 patients (80%) in the Cam-NP arm and 27 patients (96.4%) in the NP arm had died."
40554667
sparser
"The median progression-free survival (PFS) was significantly longer in the Cam-NP arm (5.62 months, 95% CI, 3.79-7.45) compared to the NP arm (4.21 months, 95% CI, 2.51-5.91) (log-rank P  = 0.006; HR 0.33, 95% CI, 0.14-0.76; xref )."
40554667
sparser
"At 5 months, the PFS rate was 54.7% in the Cam-NP group and 12.8% in the NP group."
40554667
sparser
"The PFS rates for the Cam-NP group at 9 and 20 months were 21% and 15.8%, respectively."
40554667
sparser
"Although the median overall survival (OS) showed a trend toward being longer in the Cam-NP group (9.8 months, 95% CI, 7.32-12.28 vs. 7.17 months, 95% CI, 3.72-10.62), this difference did not reach statistical significance (HR 0.62, 95% CI, 0.35-1.08; log-rank P  = 0.087; xref )."
40554667
sparser
"The OS rates at 12 and 24 months were 43.3% and 23.3%, respectively, for the Cam-NP group, compared to 25% and 10.7% for the NP group."
40554667
sparser
"While no statistically significant differences in OS were observed in subgroup analyses, a trend toward longer OS was found in males and patients without ascites in the Cam-NP group compared to the NP group (14.24 months vs. 8.45 months, log-rank P  = ."
40554667
sparser
"Skin toxicity, including erythema and pruritus, was more frequent in the Cam-NP group (6.7% vs. 3.6%)."
40554667
sparser
"More than 30% of patients in the Cam-NP arm experienced elevated ALT (alanine aminotransferase) or AST (aspartate aminotransferase) levels, while the incidence in the NP arm was under 15%."
40554667
sparser
"Hypoalbuminemia was observed more frequently in the Cam-NP group (23.4% vs. 7.1%)."
40554667
sparser
"Two participants in the Cam-NP group and nine participants in the NP group did not complete computed tomography (CT) imaging after 1 or 2 treatment cycles."
40554667
sparser
"The median duration of response was longer in the Cam-NP group (4.64 months vs. 2.96 months, P  = ."
40554667